By combining their technology, data and expertise, MMIT and Evaluate will become a $1.6 billion global pharma commercial intelligence provider

For the full press release: https://hgcapital.com/mmit-and-evaluate-join-forces-to-offer-an-end-to-end-view-of-the-pharmaceutical-market-landscape/ 

Yardley, Pa.-based Managed Markets Insight & Technology (MMIT), LLC, the trusted go-to-market partner solely focused on solving the “what and why” of market access, has joined forces with London-based Evaluate, a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry. This newly merged organization will offer customers a unique and comprehensive data solution offering both analytical and predictive data insights across the entire drug life cycle.

“MMIT and Evaluate share a mission of helping patients get access to lifesaving therapies. As customers’ decision-making processes become increasingly more centralized, we couldn’t be more thrilled to come together and offer a comprehensive solution for bringing new drugs to market and to patients.”

Mike Gallup, CEO of MMIT

The two organizations will become a leading pharma commercial intelligence provider—one that aims to inform and support customers from pipeline to prescription. Combining Evaluate’s data-driven understanding of commercial opportunities with MMIT’s insight into patient coverage will offer customers an end-to-end view of the pharmaceutical market landscape, allowing them to enhance high-value strategic portfolio decisions, assess unmet needs, evaluate barriers to access, and develop pricing strategies and value propositions to ensure that treatments get in the hands of patients.

“It’s an exciting time for our new combined organization. Evaluate and MMIT have a shared vision to enhance patient outcomes by helping them access innovative treatments faster. Together, we are better placed to help our customers identify and evaluate strategic, valuable R&D investments and smooth access to therapies for those who need it the most—the patients.”

Deborah Kobewka, Evaluate CEO

Deborah Kobewka will continue in her role as Evaluate’s CEO, while MMIT’s CEO, Mike Gallup, will be CEO of the combined entity. Upon completion of the merger, MMIT’s equity partner, Welsh, Carson, Anderson & Stowe (WCAS), and Evaluate’s equity partner, Hg, will share joint control of the combined business.

“There are enormous growth opportunities ahead for this combined business with over 1,300 global customers, highly complementary solutions and differentiated offerings in the market. We are delighted to continue partnering with the management team at MMIT while welcoming the team from Evaluate and our new partner, Hg.”

Ed Sobol, General Partner at WCAS

“This combination brings together two high-quality businesses and teams to form a new global player in commercial pharma intelligence, delivering better outcomes to the entire healthcare ecosystem and helping patients access treatments more efficiently. “We’re proud of what we’ve achieved alongside the Evaluate team to date and are excited to partner with WCAS and MMIT in supporting the accelerated growth of this new combined business.”

David Issott, Partner at Hg

The terms of the transaction have not been disclosed and completion is subject to customary closing conditions.

Anonymous